Tardive dyskinesia is sometimes reversible, but full remission is far from guaranteed. Long-term studies report remission rates that vary widely, from near zero to 73%, though most find that fewer than 25% of people experience complete resolution of symptoms. The odds depend heavily on how early the condition is caught, how long you were exposed to the medication that caused it, your age, and whether you can safely stop or switch that medication.
Why Symptoms Often Persist After Stopping Medication
Tardive dyskinesia develops because medications that block dopamine receptors, most commonly antipsychotics, cause lasting changes in how the brain processes dopamine signaling. The risk isn’t tied to peak drug levels in your system but to sustained receptor blockade over time. The longer and more intensely those receptors are blocked, the more entrenched those brain changes become.
This is why stopping the medication doesn’t automatically fix the problem. In one retrospective study of 106 patients who discontinued their dopamine-blocking medications, the rate of spontaneous remission was only 2%. Even with targeted treatment after stopping the drug, overall remission reached just 13%. That said, the same study noted a general tendency toward improvement in most patients, meaning symptoms often get better even when they don’t disappear entirely.
The 18-Month Window
If you’re able to stay off the causative medication, improvement tends to happen gradually over months to years rather than weeks. One study estimated that if a person remains off their antipsychotic for 18 months, the probability of seeing at least a 50% reduction in involuntary movements is about 87%. That’s a meaningful improvement for most people, even if it falls short of complete remission. The takeaway: reversibility is a slow process, and patience matters.
Factors That Affect Your Chances of Recovery
Not everyone faces the same odds. Several factors strongly predict whether symptoms will fade or stick around:
- Age: Younger people have significantly higher chances of recovery after stopping the causative medication. Older adults are less likely to improve.
- How early it’s caught: The duration of untreated symptoms is one of the strongest predictors of long-term persistence. The sooner tardive dyskinesia is identified and addressed, the better the outcome.
- Severity at diagnosis: People with mild, localized movements are more likely to improve than those with severe or widespread involuntary movements.
- Cumulative drug exposure: Longer use and higher doses of dopamine-blocking medications correlate with worse recovery prospects. The condition can develop even with short-term exposure in vulnerable individuals, and rare cases have appeared after a single dose in older adults.
- Ability to stop or reduce the medication: People who can taper off or discontinue their antipsychotic show higher rates of improvement. Those who need to stay on high-dose treatment generally have less favorable outcomes.
- Other health conditions: Diabetes and cognitive impairment tend to prolong the course of tardive dyskinesia.
Why Stopping the Medication Isn’t Always Possible
The first-line approach to managing tardive dyskinesia is withdrawing the antipsychotic if it’s clinically safe to do so. For people who don’t have a psychotic disorder and developed TD from a medication prescribed for nausea, mood, or another condition, a slow and gradual taper over weeks to months is often reasonable.
For most people with schizophrenia, however, stopping antipsychotic therapy simply isn’t an option because of the risk of psychiatric relapse. In these cases, switching from an older, high-potency antipsychotic to one with lower dopamine-blocking activity (such as clozapine or quetiapine) can reduce TD symptoms while still managing the underlying condition. Notably, simply lowering the dose of the current medication doesn’t have strong evidence behind it as a standalone strategy.
Medications That Reduce Symptoms
Two medications are now FDA-approved specifically for tardive dyskinesia. Both work by regulating how dopamine is packaged and released in the brain, rather than blocking receptors the way antipsychotics do.
In clinical trials, both drugs produced significant reductions in involuntary movement scores compared to placebo. At higher doses, patients saw improvements roughly 2 to 3.5 points greater than placebo on the standard movement rating scale, which clinicians use to track the severity of facial, limb, and trunk movements. These are clinically meaningful differences: enough to noticeably reduce lip smacking, tongue movements, or limb jerking in daily life. Both medications were generally well tolerated.
These treatments manage symptoms rather than cure the underlying condition. If the medication is stopped, involuntary movements often return. Still, for people who can’t discontinue their antipsychotic and are living with disruptive or socially distressing movements, symptom reduction can be life-changing.
What About Vitamin E?
Vitamin E has been studied as a potential treatment because of its antioxidant properties. The theory is that it might counteract some of the cellular damage involved in tardive dyskinesia. A Cochrane review pooling data from multiple trials found no clear evidence that vitamin E improves established symptoms. However, there were hints from small, low-quality studies that it might slow worsening of symptoms, particularly for people who developed the condition within the preceding five years. It’s not harmful at typical supplement doses, but it shouldn’t be relied on as a treatment.
How Symptoms Are Tracked Over Time
If you’re being monitored for tardive dyskinesia, your clinician will likely use a standardized exam called the AIMS (Abnormal Involuntary Movement Scale). It evaluates involuntary movements across seven body areas: facial muscles, lips, jaw, tongue, upper limbs, lower limbs, and trunk (neck, shoulders, and hips). Each area is scored on a severity scale. The exam also rates overall severity, how much the movements interfere with daily functioning, and whether you’re aware of the movements yourself. Dental status is checked too, since poorly fitting dentures can mimic or worsen oral movements.
This same scale is used to track whether your symptoms are improving, stable, or getting worse over time, making it a practical tool for measuring whether any intervention is working. If you’re told your AIMS score has dropped, that translates directly to fewer or less intense involuntary movements in specific parts of your body.